Home News Covid-19

Singapore eDevelopment subsidiary discovers potential medicines to inhibit Covid-19 in peer-reviewed scientific journal

Felicia Tan
Felicia Tan6/17/2020 06:22 PM GMT+08  • 2 min read
Singapore eDevelopment subsidiary discovers potential medicines to inhibit Covid-19 in peer-reviewed scientific journal
Singapore eDevelopment’s (SeD) wholly-owned subsidiary Impact Biomedical says that its Covid-19 research with Global Research and Discovery Group Sciences (GRDG) was published in the peer-reviewed scientific journal Molecules on June 11.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (June 17): Singapore eDevelopment’s (SeD) wholly-owned subsidiary Impact Biomedical says that its Covid-19 research with Global Research and Discovery Group Sciences (GRDG) was published in the peer-reviewed scientific journal Molecules on June 11.

The research was conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. (Vilotos).

The research paper, titled “Potential of Flavonoid-Inspired Phytomedicines against COVID-19,” indicates that the group’s research using the Equivir, Linebacker, and Caflanone compounds, may inhibit against Covid-19 receptors “equally or better” than Chloroquine, a drug currently under evaluation in clinical trials against COVID-19.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.